Next Score View the next score

    Mass. Movers

    Dyax revenue increases, loss narrows

    Shares of Burlington biopharmaceutical company Dyax Corp. rose on fourth-quarter revenue that reached $16.9 million, compared to $16.0 million last year. The loss per share narrowed to 2 cents, beating estimates of a 4-cent loss. Officials reported sales of Kalbitor, Dyax’s lead product, which treats hereditary angioedema, increased to $12.6 million, compared to $11.8 million last year. Hereditary angioedema is a rare problem with the immune system that causes swelling, particularly of the face and airways, and cramping.